Navigation Links
Encision Reports 10% Product Revenue Increase in Third Quarter of Fiscal Year 2013 Results
Date:1/28/2013

BOULDER, Colo., Jan. 28, 2013 /PRNewswire/ -- Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, today announced financial results for its fiscal 2013 third quarter ended December 31, 2012. 

The Company posted quarterly product revenue of $2.955 million and quarterly service revenue of $100 thousand for a quarterly net loss of $82 thousand, or $(0.01) per share. These results compare to product revenue of $2.689 million and service revenue of $479 thousand for a net loss of $81 thousand, or $(0.01) per share, in the year-ago quarter. Gross margin was 54.5 percent compared to 55 percent in the year-ago quarter.

The Company posted nine months product revenue of $8.566 million and nine months service revenue of $464 thousand for a nine months net loss of $337 thousand, or $(0.04) per share. These results compare to product revenue of $8.352 million and service revenue of $1.266 million for a net loss of $570 thousand, or $(0.09) per share, in the year-ago nine months. Gross margin was 56 percent compared to 53 percent in the year-ago nine months. In the year-ago nine months, our margin was lower due to a one-time charge of $430 thousand for a voluntary recall of a certain electrode product.

"We were pleased that our product revenue grew ten percent for the third quarter over last year's third quarter and five percent over this year's second quarter," said Fred Perner , President and CEO. "As we previously announced, our service revenue continues to lag last year's pace due to a project that was phased out by a strategic partner at the beginning of this fiscal year. Additionally, we continued to make investments in our quality platform and product development initiatives. In the third quarter, our inventory levels increased as we expect to introduce new products in our fourth quarter."

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2012 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

  Encision Inc. Condensed Balance Sheets(Amounts in thousands)(Unaudited)December 31,
2012March 31,
2012ASSETSCash and cash equivalents$
473$
565Accounts receivable, net1,0961,428Inventories, net2,6222,489Prepaid expenses10028Total current assets4,2914,510Equipment, net1,6601,619Patents, net228273Other assets97Total assets$ 6,188$ 6,409LIABILITIES AND SHAREHOLDERS' EQUITYAccounts payable$   694$ 1,040Accrued compensation405283Other accrued liabilities421349Total current liabilities1,5201,672Common stock and additional paid-in capital21,56521,297Accumulated (deficit)(16,897)(16,560)Total shareholders' equity4,6684,737Total liabilities and shareholders' equity$ 6,188$  6,409 Encision Inc.Condensed Statements of Operations(Amounts in thousands, except per share information)(Unaudited)Three Months EndedNine Months EndedDecember 31, 2012December 31, 2011December 31, 2012December 31, 2011Net revenue:Product$ 2,955$ 2,689$8,566$ 8,352Service1004784641,266Total revenue3,0553,1679,0309,618Cost of revenue:Product1,3171,1953,6923,981Service72231311551Total cost of revenue1,3891,4264,0034,532Gross profit1,6661,7415,0275,086Operating expenses:Sales and marketing9031,0582,7163,308General and administrative3854071,3521,289Research and development4613381,2941,011Total operating expenses1,7491,8035,3625,608Operating loss(83)(62)(335)(522)Interest and other expense, net1(19)(2)(48)Loss before provision for income taxes(82)(81)(337)(570)Provision for income taxes– –– –– –– –Net loss$  (82)$  (81)$
(337)$  (570)Net loss per share—basic and diluted$ (0.01)$ (0.01)$   (0.04)$ (0.09)Basic and diluted weighted average number of shares8,2106,4558,1976,455 


'/>"/>
SOURCE Encision Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision Reports Second Quarter of Fiscal Year 2013 Results
2. Encision Reports First Quarter of Fiscal Year 2013 Results
3. Education and Collaboration Key to Continued Progress in Fighting Rogue Online Prescription Drug Sellers, Reports NABP
4. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
5. Cepheid Reports Fourth Quarter And Full Year 2012 Results
6. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
7. Hill-Rom Reports Fiscal First Quarter Results; Updates 2013 Financial Outlook For R&D Tax Credit Reinstatement
8. Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2013
9. MGC Diagnostics Corporation Reports Fourth Quarter and Fiscal Year 2012 Operating Results
10. Avanir Pharmaceuticals Reports Fiscal 2012 Fourth Quarter And Year-End Financial And Business Results
11. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... 2017 It should come as no surprise to ... in the midst of a crippling opioid epidemic. According to ... number of overdose deaths from opiate-based medications has quadrupled, Says, ... million dead from 2001 to 2015". During this time, the ... similarly quadrupled, drawing a compelling link between prescription and eventual ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a ... it has partnered with WALLIX to expand its solution to help government ... There are a number of ways to address the authentication requirements within NIST ...
(Date:7/24/2017)... Solana Beach, California (PRWEB) , ... July 24, ... ... and commercialization of autologous fat (adipose) transfer systems announces the issuance of United ... (the ‘324 patent) for its adipose filtration technology. The '398 and '324 ...
(Date:7/24/2017)... Georgia (PRWEB) , ... July 24, 2017 , ... ... comprehensive sleep management solution focused on delivering end-to-end sleep health care ... program. , Recent literature shows that adherence rates for positive airway pressure (PAP) ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... today CURE announced that they have enrolled over 100,000 children in their treatment ... children born every year in areas where treatment is limited or non-existent. Without ...
(Date:7/24/2017)... Binzhou, Shandong Province (PRWEB) , ... July 24, ... ... Traditional Chinese Medicine's "Chinese Medicine Clinical Vitiligo Hospital" was set up, and the ... State Administration of traditional Chinese medicine, the head of the army's health system, ...
Breaking Medicine News(10 mins):